INS and depressive symptom measurement: After adjusting for multiple confounding factors, including age, sex, BMI (≥25 vs. <25 kg/m2), changes in depression scores expressed by HDRS change, and insulin use, choline alphoscerate use was associated with increased odds for a reduction in WC (OR 18.28 [95% CI 2.27–461.35]) and decreased odds for a high LDL/HDL ratio at 6 months (OR 0.16 [95% CI 0.03–0.76]).